ES2515170T3 - Gen de fusión EML4-ALK - Google Patents

Gen de fusión EML4-ALK Download PDF

Info

Publication number
ES2515170T3
ES2515170T3 ES09006058.3T ES09006058T ES2515170T3 ES 2515170 T3 ES2515170 T3 ES 2515170T3 ES 09006058 T ES09006058 T ES 09006058T ES 2515170 T3 ES2515170 T3 ES 2515170T3
Authority
ES
Spain
Prior art keywords
alk
eml4
polypeptide
seq
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09006058.3T
Other languages
English (en)
Spanish (es)
Inventor
Hiroyuki Mano
Sadao Kuromitsu
Nobuaki Shindo
Takatoshi Soga
Takashi Furutani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
CureGene KK
Original Assignee
Astellas Pharma Inc
CureGene KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, CureGene KK filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ES2515170T3 publication Critical patent/ES2515170T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES09006058.3T 2006-10-11 2007-10-11 Gen de fusión EML4-ALK Active ES2515170T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2006277718 2006-10-11
JP2006277718 2006-10-11
JP2007120670 2007-05-01
JP2007120670 2007-05-01
CA2598893 2007-08-24
CA 2598893 CA2598893C (en) 2006-10-11 2007-08-24 Eml4-alk fusion gene

Publications (1)

Publication Number Publication Date
ES2515170T3 true ES2515170T3 (es) 2014-10-29

Family

ID=39277176

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09006058.3T Active ES2515170T3 (es) 2006-10-11 2007-10-11 Gen de fusión EML4-ALK
ES07254044T Active ES2335368T3 (es) 2006-10-11 2007-10-11 Gen de fusion eml4-alk.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07254044T Active ES2335368T3 (es) 2006-10-11 2007-10-11 Gen de fusion eml4-alk.

Country Status (7)

Country Link
US (7) US7728120B2 (cg-RX-API-DMAC7.html)
EP (1) EP2116553B1 (cg-RX-API-DMAC7.html)
JP (2) JP4303303B2 (cg-RX-API-DMAC7.html)
AT (1) ATE450547T1 (cg-RX-API-DMAC7.html)
CA (1) CA2598893C (cg-RX-API-DMAC7.html)
DE (1) DE602007003543D1 (cg-RX-API-DMAC7.html)
ES (2) ES2515170T3 (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
DK2016089T3 (da) * 2006-04-14 2014-04-22 Cell Signaling Technology Inc Gendefekter og mutant-alk-kinase i humane faste tumorer
EP2447360A1 (en) * 2006-04-14 2012-05-02 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
AU2009215168A1 (en) * 2008-02-12 2009-08-20 Dana-Farber Cancer Institute Fish assay for EML4 and ALK fusion in lung cancer
JP2009219728A (ja) * 2008-03-18 2009-10-01 Daito Giken:Kk 遊技台
PL2300013T5 (pl) 2008-05-21 2025-04-28 Takeda Pharmaceutical Company Limited Pochodne fosforu jako inhibitor kinazy
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP2432900A4 (en) * 2009-05-15 2012-11-21 Insight Genetics Inc METHOD AND COMPOSITIONS RELATED TO ALK FUSIONS FOR DIAGNOSIS AND TREATMENT OF CANCER
EP2487250A4 (en) * 2009-10-06 2013-03-20 Fujirebio Kk METHOD FOR DETECTING FUSION GENES
WO2011087709A2 (en) 2009-12-22 2011-07-21 Quest Diagnostics Investments Incorporated Eml4-alk translocations in lung cancer
EP2540822B1 (en) * 2010-02-22 2017-05-03 Fujirebio Inc. Method for identification of oncogene, method for establishment of cell capable of expressing oncogene, and method for screening for oncogene-targeting substance
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
WO2011130635A2 (en) * 2010-04-16 2011-10-20 Response Genetics, Inc. Primers, probes, methods and kits for the detection of eml4-alk variants
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
RU2573392C3 (ru) 2010-08-20 2021-06-24 Чугаи Сейяку Кабусики Кайся Композиция, содержащая тетрациклические соединения
KR101583589B1 (ko) * 2010-09-02 2016-01-08 구루메 다이가쿠 단분자 ｄｎａ로 형성되는 환상 ｄｎａ의 작성 방법
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
JP5769952B2 (ja) * 2010-11-12 2015-08-26 株式会社Ｌｓｉメディエンス Ｅｍｌ４−ａｌｋ融合遺伝子の高感度検出方法
WO2012075318A2 (en) * 2010-12-01 2012-06-07 Cell Signaling Technology, Inc. Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
MX2013008791A (es) * 2011-02-02 2013-10-07 Irm Llc Metodos para usar inhibidores de alk.
US20140296181A1 (en) * 2011-04-07 2014-10-02 Coferon, Inc. Methods of modulating oncogenic fusion proteins
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CN103890175B (zh) 2011-08-31 2015-12-09 学校法人久留米大学 在dna分子的环化中仅选择由单分子形成的环化dna的方法
PL2838998T3 (pl) 2012-04-18 2018-04-30 Cell Signaling Technology, Inc. EGFR i ROS1 w nowotworze
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9084456B1 (en) * 2012-05-28 2015-07-21 Jack Zemer Linkage for jewelry components
US9597348B2 (en) 2012-09-06 2017-03-21 Epizyme, Inc. Method of treating leukemia
US20150342979A1 (en) * 2012-12-21 2015-12-03 Epizyme, Inc. Dot1l inhibitors for use in the treatment of leukemia
HK1211235A1 (en) 2013-02-22 2016-05-20 霍夫曼-拉罗奇有限公司 Methods of treating cancer and preventing drug resistance
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
JP6534930B2 (ja) 2013-07-26 2019-06-26 公益財団法人がん研究会 Ｎｔｒｋ３融合体の検出法
JP6806440B2 (ja) * 2013-10-29 2021-01-06 公益財団法人がん研究会 新規融合体及びその検出法
WO2015064621A1 (ja) * 2013-10-29 2015-05-07 公益財団法人がん研究会 新規融合体及びその検出法
WO2015111716A1 (ja) 2014-01-24 2015-07-30 公益財団法人がん研究会 新規融合体及びその検出法
PL3135287T3 (pl) 2014-04-25 2025-03-31 Chugai Seiyaku Kabushiki Kaisha Preparat zawierający związek tetracykliczny w dużej dawce
JP6873698B2 (ja) 2014-04-25 2021-05-19 中外製薬株式会社 ４環性化合物の新規結晶
TWI765410B (zh) 2014-08-08 2022-05-21 日商中外製藥股份有限公司 ４環性化合物的非晶質體的用途
US10597725B2 (en) * 2014-09-01 2020-03-24 Arkray, Inc. Primer reagent for amplifying ALK fusion gene, ALK fusion gene amplification reagent kit including the same, and ALK fusion gene amplification method and ALK fusion gene analysis method using the same
JP7015171B2 (ja) 2016-01-15 2022-02-02 公益財団法人がん研究会 新規融合体及びその検出法
JP6740172B2 (ja) * 2017-05-02 2020-08-12 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
WO2020006314A1 (en) * 2018-06-27 2020-01-02 City Of Hope Modification of small rnas for therapeutic uses
CN112384223B (zh) 2018-06-29 2024-08-27 中外制药株式会社 含有难溶性碱性药剂的药物组合物
JP7385191B2 (ja) * 2019-08-30 2023-11-22 学校法人同志社 Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬
JP2020156481A (ja) * 2020-04-06 2020-10-01 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
JPWO2023074785A1 (cg-RX-API-DMAC7.html) 2021-10-28 2023-05-04
IL317839A (en) 2022-07-04 2025-02-01 Chugai Pharmaceutical Co Ltd Combination drug
CN119789871A (zh) 2022-08-30 2025-04-08 中外制药株式会社 并用药物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034785A1 (en) 1999-11-11 2001-05-17 Yamanouchi Pharmaceutical Co., Ltd. Novel metalloprotease having aggrecanase activity
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
SI2287156T1 (sl) 2003-08-15 2013-09-30 Novartis Ag 2,4-di(fenilamino)-pirimidini, uporabni pri zdravljenju neoplastičnih bolezni, vnetnih motenj in motenj imunskega sistema
WO2005097765A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
DK2016089T3 (da) 2006-04-14 2014-04-22 Cell Signaling Technology Inc Gendefekter og mutant-alk-kinase i humane faste tumorer
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物

Also Published As

Publication number Publication date
US9029521B2 (en) 2015-05-12
ATE450547T1 (de) 2009-12-15
CA2598893A1 (en) 2008-04-11
US20130158095A1 (en) 2013-06-20
US20100240673A1 (en) 2010-09-23
US20090099193A1 (en) 2009-04-16
US8197818B2 (en) 2012-06-12
US20080090776A1 (en) 2008-04-17
CA2598893C (en) 2012-04-10
US20150184161A1 (en) 2015-07-02
ES2335368T3 (es) 2010-03-25
EP2116553B1 (en) 2014-07-30
JP4303303B2 (ja) 2009-07-29
JP2008295444A (ja) 2008-12-11
JP5172736B2 (ja) 2013-03-27
US20110230545A1 (en) 2011-09-22
US7605131B2 (en) 2009-10-20
US20180066266A1 (en) 2018-03-08
JP2009100783A (ja) 2009-05-14
US9932589B2 (en) 2018-04-03
US7964710B2 (en) 2011-06-21
EP2116553A1 (en) 2009-11-11
US7728120B2 (en) 2010-06-01
DE602007003543D1 (de) 2010-01-14

Similar Documents

Publication Publication Date Title
ES2515170T3 (es) Gen de fusión EML4-ALK
EP1914240B1 (en) EML4-ALK fusion gene
ES2702305T3 (es) Nuevo producto de fusión de FGFR3
ES2873933T3 (es) Una mutación de MEK1 que confiere resistencia a inhibidores de RAF y de MEK
ES2622401T3 (es) Método de predicción de la eficacia de un inhibidor de la angiogénesis
JP2018521973A (ja) Ｒｔｋ突然変異細胞を有する患者を処置するための組成物及び方法
ES2576061T3 (es) Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
ES2890556T3 (es) Combinación de inhibidor de EGFR e inhibidor de MEK para su uso en el tratamiento del cáncer con mutación de NRAS
KR102127218B1 (ko) 뇌 신경 교종 치료용 약물 제조에서의 화합물의 용도
KR101775356B1 (ko) Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
ES2880085T3 (es) Uso de inhibidores de c-met para tratar cánceres que albergan mutaciones met
KR20180129585A (ko) Mage-1에 특이적으로 결합하는 압타머 및 이의 용도
Peltola NRG1/ERBB Axis in Drug Tolerance to Targeted Cancer Therapies
KR20240153453A (ko) IGFBP5 발현 억제용 shRNA를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
WO2012158880A2 (en) Anaplastic thyroid cancers harbor novel oncogenic mutations of the alk gene
JP2017042111A (ja) 癌の罹患の有無の判別方法並びに癌の治療及び／又は予防のための医薬組成物
CN115369163A (zh) Ryr2及其下调剂在治疗转移性结直肠癌中的应用
WO2004094628A1 (ja) イマチニブ耐性フィラデルフィア染色体陽性ヒト急性リンパ性白血病細胞株及びその使用